The Role of Oxidative Stress in Endothelial Dysfunction and Vascular Inflammation

Nitric Oxide

Volumn , Issue , 2010, Pages 705-754

  Osto, Elena ^a   Cosentino, Francesco ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Aging; Atherosclerosis; Diabetes; Endothelial dysfunction; Inflammation; Nitric oxide; Reactive oxygen species

Indexed keywords

EID: 78049239775     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-373866-0.00022-8     Document Type: Chapter

References (305)

1. Abid M.R., Tsai J.C., Spokes K.C., Deshpande S.S., Irani K., Aird W.C. Vascular endothelial growth factor induces manganese-superoxide dismutase expression in endothelial cells by a Rac1-regulated NADPH oxidase-dependent mechanism. FASEB J 2001, 15:2548-2550.
2. Abid M.R., Schoots I.G., Spokes K.C., Wu S.Q., Mawhinney C., Aird W.C. Vascular endothelial growth factor-mediated induction of manganese superoxide dismutase occurs through redox-dependent regulation of forkhead and IkappaB/NF-kappaB. J. Biol. Chem. 2004, 279:44030-44038.
3. Abraham N.G., Rezzani R., Rodella L., Kruger A., Taller D., Li Volti G., Goodman A.I., Kappas A. Overexpression of human heme oxygenase-1 attenuates endothelial cell sloughing in experimental diabetes. Am. J. Physiol. Heart Circ. Physiol. 2004, 287:H2468-H2477.
4. Asahara T., Murohara T., Sullivan A., Silver M., van der Zee R., Li T., Witzenbichler B., Schatteman G., Isner J.M. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275:964-967.
5. Azumi H., Inoue N., Takeshita S., Rikitake Y., Kawashima S., Hayashi Y., Itoh H., Yokoyama M. Expression of NADH/NADPH oxidase p22phox in human coronary arteries. Circulation 1999, 100:1494-1498.
6. Azumi H., Inoue N., Ohashi Y., Terashima M., Mori T., Fujita H., Awano K., Kobayashi K., Maeda K., Hata K., Shinke T., Kobayashi S., Hirata K., Kawashima S., Itabe H., Hayashi Y., Imajoh-Ohmi S., Itoh H., Yokoyama M. Superoxide generation in directional coronary atherectomy specimens of patients with angina pectoris: important role of NAD(P)H oxidase. Arterioscler Thromb. Vasc. Biol. 2002, 22:1838-1844.
7. Babior B.M. The respiratory burst oxidase. Hematol. Oncol. Clin. North. Am. 1988, 2:201-212.
8. Babior B.M. NADPH oxidase. Curr. Opin. Immunol. 2004, 16:42-47.
9. Bachetti T., Comini L., Francolini G., Bastianon D., Valetti B., Cadei M., Grigolato P., Suzuki H., Finazzi D., Albertini A., Curello S., Ferrari R. Arginase pathway in human endothelial cells in pathophysiological conditions. J. Mol. Cell Cardiol. 2004, 37:515-523.
10. Ballard V.L., Edelberg J.M. Stem cells and the regeneration of the aging cardiovascular system. Circ. Res. 2007, 100:1116-1127.
11. Ballinger S.W. Mitochondrial dysfunction in cardiovascular disease. Free Radic. Biol. Med. 2005, 38:1278-1295.
12. Ballinger S.W., Patterson C., Yan C.N., Doan R., Burow D.L., Young C.G., Yakes F.M., Van Houten B., Ballinger C.A., Freeman B.A., Runge M.S. Hydrogen peroxide- and peroxynitrite-induced mitochondrial DNA damage and dysfunction in vascular endothelial and smooth muscle cells. Circ. Res. 2000, 86:960-966.
13. Ballinger S.W., Patterson C., Knight-Lozano C.A., Burow D.L., Conklin C.A., Hu Z., Reuf J., Horaist C., Lebovitz R., Hunter G.C., McIntyre K., Runge M.S. Mitochondrial integrity and function in atherogenesis. Circulation 2002, 106:544-549.
14. Barton M., Cosentino F., Brandes R.P., Moreau P., Shaw S., Luscher T.F. Anatomic heterogeneity of vascular aging: role of nitric oxide and endothelin. Hypertension 1997, 30:817-824.
15. Beckman J.S., Koppenol W.H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am. J. Physiol. 1996, 271:C1424-C1437.
16. Beckman J.S., Beckman T.W., Chen J., Marshall P.A., Freeman B.A. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. U S A 1990, 87:1620-1624.
17. Beckman J.A., Goldfine A.B., Gordon M.B., Creager M.A. Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans. Circulation 2001, 103:1618-1623.
18. Beckman J.A., Creager M.A., Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. Jama 2002, 287:2570-2581.
19. Beckman J.A., Goldfine A.B., Gordon M.B., Garrett L.A., Creager M.A. Inhibition of protein kinase Cbeta prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ. Res. 2002, 90:107-111.
20. Bedard K., Krause K.H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev. 2007, 87:245-313.
21. Berkowitz D.E., White R., Li D., Minhas K.M., Cernetich A., Kim S., Burke S., Shoukas A.A., Nyhan D., Champion H.C., Hare J.M. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 2003, 108:2000-2006.
22. Berry C.E., Hare J.M. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J. Physiol. 2004, 555:589-606.
23. Blackwell K.A., Sorenson J.P., Richardson D.M., Smith L.A., Suda O., Nath K., Katusic Z.S. Mechanisms of aging-induced impairment of endothelium-dependent relaxation: role of tetrahydrobiopterin. Am. J. Physiol. Heart Circ. Physiol. 2004, 287:H2448-H2453.
24. Boger R.H., Ron E.S. L-Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor. Altern. Med. Rev. 2005, 10:14-23.
25. Bogoyevitch M.A. The isoform-specific functions of the c-Jun N-terminal Kinases (JNKs): differences revealed by gene targeting. Bioessays 2006, 28:923-934.
26. Bombeli T., Karsan A., Tait J.F., Harlan J.M. Apoptotic vascular endothelial cells become procoagulant. Blood 1997, 89:2429-2442.
27. Bonetti P.O., Lerman L.O., Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb. Vasc. Biol. 2003, 23:168-175.
28. Bonfini L., Migliaccio E., Pelicci G., Lanfrancone L., Pelicci P.G. Not all Shc's roads lead to Ras. Trends Biochem. Sci. 1996, 21:257-261.
29. Bonow R.O., Gheorghiade M. The diabetes epidemic: a national and global crisis. Am. J. Med. 2004, 116(Suppl 5A):2S-10S.
30. Bonow R.O., Smaha L.A., Smith S.C., Mensah G.A., Lenfant C. World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic. Circulation 2002, 106:1602-1605.
31. Borsello T., Clarke P.G., Hirt L., Vercelli A., Repici M., Schorderet D.F., Bogousslavsky J., Bonny C. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat. Med. 2003, 9:1180-1186.
32. Brandes R.P., Fleming I., Busse R. Endothelial aging. Cardiovasc. Res. 2005, 66:286-294.
33. Butler R., Morris A.D., Belch J.J., Hill A., Struthers A.D. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 2000, 35:746-751.
34. Buttery L.D., Springall D.R., Chester A.H., Evans T.J., Standfield E.N., Parums D.V., Yacoub M.H., Polak J.M. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab Invest. 1996, 75:77-85.
35. Cai H., Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 2000, 87:840-844.
36. Camici G.G., Schiavoni M., Francia P., Bachschmid M., Martin-Padura I., Hersberger M., Tanner F.C., Pelicci P., Volpe M., Anversa P., Luscher T.F., Cosentino F. Genetic deletion of p66(Shc) adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress. Proc. Natl. Acad. Sci. U S A 2007, 104:5217-5222.
37. Cardillo C., Kilcoyne C.M., Cannon R.O., Quyyumi A.A., Panza J.A. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension 1997, 30:57-63.
38. Carmeliet P. Angiogenesis in health and disease. Nat. Med. 2003, 9:653-660.
39. Cave A.C., Brewer A.C., Narayanapanicker A., Ray R., Grieve D.J., Walker S., Shah A.M. NADPH oxidases in cardiovascular health and disease. Antioxid. Redox Signal 2006, 8:691-728.
40. Cederbaum S.D., Yu H., Grody W.W., Kern R.M., Yoo P., Iyer R.K. Arginases I and II: do their functions overlap?. Mol. Genet. Metab. 2004, 81(Suppl 1):S38-S44.
41. Chen P.Y., Sanders P.W. Role of nitric oxide synthesis in salt-sensitive hypertension in Dahl/Rapp rats. Hypertension 1993, 22:812-818.
42. Chicoine L.G., Paffett M.L., Young T.L., Nelin L.D. Arginase inhibition increases nitric oxide production in bovine pulmonary arterial endothelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. 2004, 287:L60-L68.
43. Closs E.I., Scheld J.S., Sharafi M., Forstermann U. Substrate supply for nitric-oxide synthase in macrophages and endothelial cells: role of cationic amino acid transporters. Mol. Pharmacol. 2000, 57:68-74.
44. Collins T., Cybulsky M.I. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis?. J. Clin. Invest. 2001, 107:255-264.
45. Cooke J.P. Asymmetrical dimethylarginine: the Uber marker?. Circulation 2004, 109:1813-1818.
46. Cooke J.P., Singer A.H., Tsao P., Zera P., Rowan R.A., Billingham M.E. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J. Clin. Invest. 1992, 90:1168-1172.
47. Cosentino F., Katusic Z.S. Tetrahydrobiopterin and dysfunction of endothelial nitric oxide synthase in coronary arteries. Circulation 1995, 91:139-144.
48. Cosentino F., Luscher T.F. Maintenance of vascular integrity: role of nitric oxide and other bradykinin mediators. Eur. Heart J 1995, 16(Suppl K):4-12.
49. Cosentino F., Luscher T.F. Tetrahydrobiopterin and endothelial function. Eur. Heart J. 1998, 19(Suppl G):G3-G8.
50. Cosentino F., Hishikawa K., Katusic Z.S., Luscher T.F. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 1997, 96:25-28.
51. Cosentino F., Eto M., De Paolis P., van der Loo B., Bachschmid M., Ullrich V., Kouroedov A., Delli Gatti C., Joch H., Volpe M., Luscher T.F. High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species. Circulation 2003, 107:1017-1023.
52. Cosentino F., Hurlimann D., Delli Gatti C., Chenevard R., Blau N., Alp N.J., Channon K.M., Eto M., Lerch P., Enseleit F., Ruschitzka F., Volpe M., Luscher T.F., Noll G. Chronic treatment with tetrahydrobiopterin reverses endothelial dysfunction and oxidative stress in hypercholesterolaemia. Heart 2008, 94:487-492.
53. Creager M.A., Luscher T.F., Cosentino F., Beckman J.A. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003, 108:1527-1532.
54. Csiszar A., Ungvari Z., Edwards J.G., Kaminski P., Wolin M.S., Koller A., Kaley G. Aging-induced phenotypic changes and oxidative stress impair coronary arteriolar function. Circ. Res. 2002, 90:1159-1166.
55. Csiszar A., Labinskyy N., Smith K., Rivera A., Orosz Z., Ungvari Z. Vasculoprotective effects of anti-tumor necrosis factor-alpha treatment in aging. Am. J Pathol. 2007, 170:388-398.
56. Delli Gatti C., Osto E., Kouroedov A., Eto M., Shaw S., Volpe M., Luscher T.F., Cosentino F. Pulsatile stretch induces release of angiotensin II and oxidative stress in human endothelial cells: effects of ACE inhibition and AT1 receptor antagonism. Clin. Exp. Hypertens 2008, 30:616-627.
57. Drexler H., Zeiher A.M., Meinzer K., Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 1991, 338:1546-1550.
58. Drummond G.R., Cai H., Davis M.E., Ramasamy S., Harrison D.G. Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression by hydrogen peroxide. Circ. Res. 2000, 86:347-354.
59. Edwards A.S., Faux M.C., Scott J.D., Newton A.C. Carboxyl-terminal phosphorylation regulates the function and subcellular localization of protein kinase C betaII. J. Biol. Chem. 1999, 274:6461-6468.
60. Elion G.B., Kovensky A., Hitchings G.H. Metabolic studies of allopurinol, an inhibitor of xanthine oxidase. Biochem. Pharmacol. 1966, 15:863-880.
61. Fabris F., Zanocchi M., Bo M., Fonte G., Poli L., Bergoglio I., Ferrario E., Pernigotti L. Carotid plaque, aging, and risk factors. A study of 457 subjects. Stroke 1994, 25:1133-1140.
62. Fang J., Alderman M.H. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000, 283:2404-2410.
63. Farb A., Burke A.P., Tang A.L., Liang T.Y., Mannan P., Smialek J., Virmani R. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996, 93:1354-1363.
64. Farquharson C.A., Butler R., Hill A., Belch J.J., Struthers A.D. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002, 106:221-226.
65. Feletou M., Vanhoutte P.M. Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H985-H1002.
66. Feng J., Han J., Pearce S.F., Silverstein R.L., Gotto A.M., Hajjar D.P., Nicholson A.C. Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-gamma. J. Lipid Res. 2000, 41:688-696.
67. Finkel T., Holbrook N.J. Oxidants, oxidative stress and the biology of ageing. Nature 2000, 408:239-247.
68. Fisslthaler B., Popp R., Kiss L., Potente M., Harder D.R., Fleming I., Busse R. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 1999, 401:493-497.
69. Fleg J.L., Gerstenblith G., Zonderman A.B., Becker L.C., Weisfeldt M.L., Costa P.T., Lakatta E.G. Prevalence and prognostic significance of exercise-induced silent myocardial ischemia detected by thallium scintigraphy and electrocardiography in asymptomatic volunteers. Circulation 1990, 81:428-436.
70. Forman H.J., Fukuto J.M., Torres M. Redox signaling: thiol chemistry defines which reactive oxygen and nitrogen species can act as second messengers. Am. J. Physiol. Cell Physiol. 2004, 287:C246-C256.
71. Forstermann U., Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006, 113:1708-1714.
72. Francia P., delli Gatti C., Bachschmid M., Martin-Padura I., Savoia C., Migliaccio E., Pelicci P.G., Schiavoni M., Luscher T.F., Volpe M., Cosentino F. Deletion of p66shc gene protects against age-related endothelial dysfunction. Circulation 2004, 110:2889-2895.
73. Freedman J.E., Ting B., Hankin B., Loscalzo J., Keaney J.F., Vita J.A. Impaired platelet production of nitric oxide predicts presence of acute coronary syndromes. Circulation 1998, 98:1481-1486.
74. Fukuda Y., Teragawa H., Matsuda K., Yamagata T., Matsuura H., Chayama K. Tetrahydrobiopterin restores endothelial function of coronary arteries in patients with hypercholesterolaemia. Heart 2002, 87:264-269.
75. Fukui T., Ishizaka N., Rajagopalan S., Laursen J.B., Capers Q.t., Taylor W.R., Harrison D.G., de Leon H., Wilcox J.N., Griendling K.K. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ. Res. 1997, 80:45-51.
76. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288:373-376.
77. Ganz P., Vita J.A. Testing endothelial vasomotor function: nitric oxide, a multipotent molecule. Circulation 2003, 108:2049-2053.
78. Gibbons G.H., Dzau V.J. Molecular therapies for vascular diseases. Science 1996, 272:689-693.
79. Gilligan D.M., Guetta V., Panza J.A., Garcia C.E., Quyyumi A.A., Cannon R.O. Selective loss of microvascular endothelial function in human hypercholesterolemia. Circulation 1994, 90:35-41.
80. Giorgio M., Migliaccio E., Orsini F., Paolucci D., Moroni M., Contursi C., Pelliccia G., Luzi L., Minucci S., Marcaccio M., Pinton P., Rizzuto R., Bernardi P., Paolucci F., Pelicci P.G. Electron transfer between cytochrome c and p66Shc generates reactive oxygen species that trigger mitochondrial apoptosis. Cell 2005, 122:221-233.
81. Golino P., Piscione F., Willerson J.T., Cappelli-Bigazzi M., Focaccio A., Villari B., Indolfi C., Russolillo E., Condorelli M., Chiariello M. Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N. Engl. J. Med. 1991, 324:641-648.
82. Gonzalez M.A., Selwyn A.P. Endothelial function, inflammation, and prognosis in cardiovascular disease. Am. J. Med. 2003, 115(Suppl 8A):99S-106S.
83. Gori T., Burstein J.M., Ahmed S., Miner S.E., Al-Hesayen A., Kelly S., Parker J.D. Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study. Circulation 2001, 104:1119-1123.
84. Gornik H.L., Creager M.A. Arginine and endothelial and vascular health. J. Nutr. 2004, 134:2880S-2887S. discussion 2895S.
85. Griendling K.K. Novel NAD(P)H oxidases in the cardiovascular system. Heart 2004, 90:491-493.
86. Griendling K.K. NADPH oxidases: new regulators of old functions. Antioxid Redox Signal 2006, 8:1443-1445.
87. Griendling K.K., Minieri C.A., Ollerenshaw J.D., Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 1994, 74:1141-1148.
88. Griendling K.K., Sorescu D., Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ. Res. 2000, 86:494-501.
89. Gu L., Okada Y., Clinton S.K., Gerard C., Sukhova G.K., Libby P., Rollins B.J. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell 1998, 2:275-281.
90. Guzik T.J., Harrison D.G. Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discov Today 2006, 11:524-533.
91. Guzik T.J., West N.E., Black E., McDonald D., Ratnatunga C., Pillai R., Channon K.M. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ. Res. 2000, 86:E85-E90.
92. Guzik T.J., Mussa S., Gastaldi D., Sadowski J., Ratnatunga C., Pillai R., Channon K.M. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002, 105:1656-1662.
93. Guzik T.J., Sadowski J., Kapelak B., Jopek A., Rudzinski P., Pillai R., Korbut R., Channon K.M. Systemic regulation of vascular NAD(P)H oxidase activity and nox isoform expression in human arteries and veins. Arterioscler Thromb. Vasc. Biol. 2004, 24:1614-1620.
94. Guzik T.J., Sadowski J., Guzik B., Jopek A., Kapelak B., Przybylowski P., Wierzbicki K., Korbut R., Harrison D.G., Channon K.M. Coronary artery superoxide production and nox isoform expression in human coronary artery disease. Arterioscler Thromb. Vasc. Biol. 2006, 26:333-339.
95. Guzik T.J., Chen W., Gongora M.C., Guzik B., Lob H.E., Mangalat D., Hoch N., Dikalov S., Rudzinski P., Kapelak B., Sadowski J., Harrison D.G. Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease. J. Am. Coll. Cardiol. 2008, 52:1803-1809.
96. Hagenfeldt L., Dahlquist G., Persson B. Plasma amino acids in relation to metabolic control in insulin-dependent diabetic children. Acta Paediatr. Scand. 1989, 78:278-282.
97. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005, 352:1685-1695.
98. Harris M.I., Flegal K.M., Cowie C.C., Eberhardt M.S., Goldstein D.E., Little R.R., Wiedmeyer H.M., Byrd-Holt D.D. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998, 21:518-524.
99. Hein T.W., Zhang C., Wang W., Chang C.I., Thengchaisri N., Kuo L. Ischemia-reperfusion selectively impairs nitric oxide-mediated dilation in coronary arterioles: counteracting role of arginase. FASEB J 2003, 17:2328-2330.
100. Heistad D.D., Armstrong M.L. Sick vessel syndrome. Can atherosclerotic arteries recover?. Circulation 1994, 89:2447-2450.
101. Heitzer T., Brockhoff C., Mayer B., Warnholtz A., Mollnau H., Henne S., Meinertz T., Munzel T. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: evidence for a dysfunctional nitric oxide synthase. Circ. Res. 2000, 86:E36-E41.
102. Heitzer T., Krohn K., Albers S., Meinertz T. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus. Diabetologia 2000, 43:1435-1438.
103. Herman A.G., Moncada S. Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis. Eur. Heart J 2005, 26:1945-1955.
104. Higashi Y., Sasaki S., Nakagawa K., Fukuda Y., Matsuura H., Oshima T., Chayama K. Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals. Am. J. Hypertens 2002, 15:326-332.
105. Hink U., Li H., Mollnau H., Oelze M., Matheis E., Hartmann M., Skatchkov M., Thaiss F., Stahl R.A., Warnholtz A., Meinertz T., Griendling K., Harrison D.G., Forstermann U., Munzel T. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ. Res. 2001, 88:E14-E22.
106. Hirosumi J., Tuncman G., Chang L., Gorgun C.Z., Uysal K.T., Maeda K., Karin M., Hotamisligil G.S. A central role for JNK in obesity and insulin resistance. Nature 2002, 420:333-336.
107. Ho F.M., Lin W.W., Chen B.C., Chao C.M., Yang C.R., Lin L.Y., Lai C.C., Liu S.H., Liau C.S. High glucose-induced apoptosis in human vascular endothelial cells is mediated through NF-kappaB and c-Jun NH2-terminal kinase pathway and prevented by PI3K/Akt/eNOS pathway. Cell Signal 2006, 18:391-399.
108. Horbinski C., Chu C.T. Kinase signaling cascades in the mitochondrion: a matter of life or death. Free Radic. Biol. Med. 2005, 38:2-11.
109. Ichijo H. From receptors to stress-activated MAP kinases. Oncogene 1999, 18:6087-6093.
110. Ide T., Tsutsui H., Kinugawa S., Suematsu N., Hayashidani S., Ichikawa K., Utsumi H., Machida Y., Egashira K., Takeshita A. Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. Circ. Res. 2000, 86:152-157.
111. Idris I., Gray S., Donnelly R. Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes. Diabetologia 2001, 44:659-673.
112. Ignarro L.J., Byrns R.E., Buga G.M., Wood K.S. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ. Res. 1987, 61:866-879.
113. Imaizumi T., Hirooka Y., Masaki H., Harada S., Momohara M., Tagawa T., Takeshita A. Effects of L-arginine on forearm vessels and responses to acetylcholine. Hypertension 1992, 20:511-517.
114. Inoguchi T., Battan R., Handler E., Sportsman J.R., Heath W., King G.L. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc. Natl. Acad. Sci. U S A 1992, 89:11059-11063.
115. Inoue H., Yokoyama C., Hara S., Tone Y., Tanabe T. Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element. J. Biol. Chem. 1995, 270:24965-24971.
116. Ischiropoulos H., al-Mehdi A.B. Peroxynitrite-mediated oxidative protein modifications. FEBS Lett. 1995, 364:279-282.
117. Jaeschke A., Rincon M., Doran B., Reilly J., Neuberg D., Greiner D.L., Shultz L.D., Rossini A.A., Flavell R.A., Davis R.J. Disruption of the Jnk2 (Mapk9) gene reduces destructive insulitis and diabetes in a mouse model of type I diabetes. Proc. Natl. Acad. Sci. U S A 2005, 102:6931-6935.
118. Jessup W., Squires B., Kritharides L., Hume D.A., Dean R.T. Effects of CSF-1 on cholesterol accumulation and efflux by macrophages. Arterioscler Thromb. Vasc. Biol. 1997, 17:18-25.
119. Johnson F.K., Johnson R.A., Peyton K.J., Durante W. Arginase inhibition restores arteriolar endothelial function in Dahl rats with salt-induced hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005, 288:R1057-R1062.
120. Kaiser N., Sasson S., Feener E.P., Boukobza-Vardi N., Higashi S., Moller D.E., Davidheiser S., Przybylski R.J., King G.L. Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells. Diabetes 1993, 42:80-89.
121. Kannel W.B., Dawber T.R., Kagan A., Revotskie N., Stokes J. Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study. Ann. Intern. Med. 1961, 55:33-50.
122. Katusic Z.S., d'Uscio L.V., Nath K.A. Vascular protection by tetrahydrobiopterin: progress and therapeutic prospects. Trends Pharmacol. Sci. 2009, 30:48-54.
123. Kawamoto A., Gwon H.C., Iwaguro H., Yamaguchi J.I., Uchida S., Masuda H., Silver M., Ma H., Kearney M., Isner J.M., Asahara T. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 2001, 103:634-637.
124. Kerr S., Brosnan M.J., McIntyre M., Reid J.L., Dominiczak A.F., Hamilton C.A. Superoxide anion production is increased in a model of genetic hypertension: role of the endothelium. Hypertension 1999, 33:1353-1358.
125. King G.L. The role of hyperglycaemia and hyperinsulinaemia in causing vascular dysfunction in diabetes. Ann. Med. 1996, 28:427-432.
126. King H., Aubert R.E., Herman W.H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998, 21:1414-1431.
127. Kinlay S., Libby P., Ganz P. Endothelial function and coronary artery disease. Curr. Opin. Lipidol. 2001, 12:383-389.
128. Kita T., Kume N., Minami M., Hayashida K., Murayama T., Sano H., Moriwaki H., Kataoka H., Nishi E., Horiuchi H., Arai H., Yokode M. Role of oxidized LDL in atherosclerosis. Ann. N Y Acad. Sci. 2001, 947:199-205. discussion 205-6.
129. Kolodgie F.D., Gold H.K., Burke A.P., Fowler D.R., Kruth H.S., Weber D.K., Farb A., Guerrero L.J., Hayase M., Kutys R., Narula J., Finn A.V., Virmani R. Intraplaque hemorrhage and progression of coronary atheroma. N. Engl. J. Med. 2003, 349:2316-2325.
130. Kosswig N., Rice S., Daugherty A., Post S.R. Class A scavenger receptor-mediated adhesion and internalization require distinct cytoplasmic domains. J. Biol. Chem. 2003, 278:34219-34225.
131. Kouroedov A., Eto M., Joch H., Volpe M., Luscher T.F., Cosentino F. Selective inhibition of protein kinase Cbeta2 prevents acute effects of high glucose on vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 2004, 110:91-96.
132. Kruth H.S. Sequestration of aggregated low-density lipoproteins by macrophages. Curr. Opin. Lipidol. 2002, 13:483-488.
133. Kubes P., Suzuki M., Granger D.N. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci. U S A 1991, 88:4651-4655.
134. Kurose I., Kubes P., Wolf R., Anderson D.C., Paulson J., Miyasaka M., Granger D.N. Inhibition of nitric oxide production. Mechanisms of vascular albumin leakage. Circ. Res. 1993, 73:164-171.
135. Kuzkaya N., Weissmann N., Harrison D.G., Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J. Biol. Chem. 2003, 278:22546-22554.
136. Kwon H.M., Sangiorgi G., Ritman E.L., McKenna C., Holmes D.R., Schwartz R.S., Lerman A. Enhanced coronary vasa vasorum neovascularization in experimental hypercholesterolemia. J. Clin. Invest. 1998, 101:1551-1556.
137. Kyriakis J.M., Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 2001, 81:807-869.
138. Lakatta E.G. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part III: cellular and molecular clues to heart and arterial aging. Circulation 2003, 107:490-497.
139. Lakatta E.G., Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a "set up" for vascular disease. Circulation 2003, 107:139-146.
140. Lakatta E.G., Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease. Circulation 2003, 107:346-354.
141. Lambeth J.D., Cheng G., Arnold R.S., Edens W.A. Novel homologs of gp91phox. Trends Biochem. Sci. 2000, 25:459-461.
142. Landmesser U., Dikalov S., Price S.R., McCann L., Fukai T., Holland S.M., Mitch W.E., Harrison D.G. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J. Clin. Invest. 2003, 111:1201-1209.
143. Landmesser U., Hornig B., Drexler H. Endothelial function: a critical determinant in atherosclerosis?. Circulation 2004, 109:II27-II33.
144. Landmesser U., Spiekermann S., Preuss C., Sorrentino S., Fischer D., Manes C., Mueller M., Drexler H. Angiotensin II induces endothelial xanthine oxidase activation: role for endothelial dysfunction in patients with coronary disease. Arterioscler Thromb Vasc. Biol. 2007, 27:943-948.
145. Laursen J.B., Somers M., Kurz S., McCann L., Warnholtz A., Freeman B.A., Tarpey M., Fukai T., Harrison D.G. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 2001, 103:1282-1288.
146. Lee T.S., Saltsman K.A., Ohashi H., King G.L. Activation of protein kinase C by elevation of glucose concentration: proposal for a mechanism in the development of diabetic vascular complications. Proc. Natl. Acad. Sci. U S A 1989, 86:5141-5145.
147. Leeuwenburgh C., Hardy M.M., Hazen S.L., Wagner P., Oh-ishi S., Steinbrecher U.P., Heinecke J.W. Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerotic intima. J. Biol. Chem. 1997, 272:1433-1436.
148. Lefer D.J., Scalia R., Campbell B., Nossuli T., Hayward R., Salamon M., Grayson J., Lefer A.M. Peroxynitrite inhibits leukocyte-endothelial cell interactions and protects against ischemia-reperfusion injury in rats. J. Clin. Invest 1997, 99:684-691.
149. Leopold J.A., Loscalzo J. Oxidative enzymopathies and vascular disease. Arterioscler Thromb Vasc. Biol. 2005, 25:1332-1340.
150. Lerman A., Zeiher A.M. Endothelial function: cardiac events. Circulation 2005, 111:363-368.
151. Lessner S.M., Prado H.L., Waller E.K., Galis Z.S. Atherosclerotic lesions grow through recruitment and proliferation of circulating monocytes in a murine model. Am. J. Pathol. 2002, 160:2145-2155.
152. Li A.C., Glass C.K. The macrophage foam cell as a target for therapeutic intervention. Nat. Med. 2002, 8:1235-1242.
153. Li J.M., Shah A.M. Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004, 287:R1014-R1030.
154. Li H., Cybulsky M.I., Gimbrone M.A., Libby P. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb. 1993, 13:197-204.
155. Li H., Meininger C.J., Hawker J.R., Haynes T.E., Kepka-Lenhart D., Mistry S.K., Morris S.M., Wu G. Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am. J. Physiol. Endocrinol Metab. 2001, 280:E75-E82.
156. Li H., Wallerath T., Munzel T., Forstermann U. Regulation of endothelial-type NO synthase expression in pathophysiology and in response to drugs. Nitric Oxide 2002, 7:149-164.
157. Li L., Sawamura T., Renier G. Glucose enhances human macrophage LOX-1 expression: role for LOX-1 in glucose-induced macrophage foam cell formation. Circ. Res. 2004, 94:892-901.
158. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
159. Liu S., Beckman J.S., Ku D.D. Peroxynitrite, a product of superoxide and nitric oxide, produces coronary vasorelaxation in dogs. J. Pharmacol. Exp. Ther. 1994, 268:1114-1121.
160. Llaverias G., Noe V., Penuelas S., Vazquez-Carrera M., Sanchez R.M., Laguna J.C., Ciudad C.J., Alegret M. Atorvastatin reduces CD68, FABP4, and HBP expression in oxLDL-treated human macrophages. Biochem. Biophys. Res. Commun. 2004, 318:265-274.
161. van der Loo B., Labugger R., Skepper J.N., Bachschmid M., Kilo J., Powell J.M., Palacios-Callender M., Erusalimsky J.D., Quaschning T., Malinski T., Gygi D., Ullrich V., Luscher T.F. Enhanced peroxynitrite
162. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ. Res. 2001, 88:756-762.
163. Loscalzo J. Adverse effects of supplemental L-arginine in atherosclerosis: consequences of methylation stress in a complex catabolism?. Arterioscler Thromb Vasc. Biol. 2003, 23:3-5.
164. Loscalzo J. L-arginine and atherothrombosis. J. Nutr. 2004, 134:2798S-2800S. discussion 2818S-2819S.
165. Ludmer P.L., Selwyn A.P., Shook T.L., Wayne R.R., Mudge G.H., Alexander R.W., Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N. Engl. J. Med. 1986, 315:1046-1051.
166. Luscher T.F., Barton M. Biology of the endothelium. Clin. Cardiol. 1997, 20:II-3-II-10.
167. Luscher T.F., Creager M.A., Beckman J.A., Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part II. Circulation 2003, 108:1655-1661.
168. Ma X.L., Lopez B.L., Liu G.L., Christopher T.A., Gao F., Guo Y., Feuerstein G.Z., Ruffolo R.R., Barone F.C., Yue T.L. Hypercholesterolemia impairs a detoxification mechanism against peroxynitrite and renders the vascular tissue more susceptible to oxidative injury. Circ. Res. 1997, 80:894-901.
169. Maier W., Cosentino F., Lutolf R.B., Fleisch M., Seiler C., Hess O.M., Meier B., Luscher T.F. Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease. J. Cardiovasc. Pharmacol. 2000, 35:173-178.
170. Mak K.H., Moliterno D.J., Granger C.B., Miller D.P., White H.D., Wilcox R.G., Califf R.M., Topol E.J. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J. Am. Coll. Cardiol. 1997, 30:171-179.
171. Malmberg K., Yusuf S., Gerstein H.C., Brown J., Zhao F., Hunt D., Piegas L., Calvin J., Keltai M., Budaj A. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000, 102:1014-1019.
172. Marsden P.A., Heng H.H., Scherer S.W., Stewart R.J., Hall A.V., Shi X.M., Tsui L.C., Schappert K.T. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J. Biol. Chem. 1993, 268:17478-17488.
173. Martino F., Loffredo L., Carnevale R., Sanguigni V., Martino E., Catasca E., Zanoni C., Pignatelli P., Violi F. Oxidative stress is associated with arterial dysfunction and enhanced intima-media thickness in children with hypercholesterolemia: the potential role of nicotinamide-adenine dinucleotide phosphate oxidase. Pediatrics 2008, 122:e648-e655.
174. Mason D.P., Kenagy R.D., Hasenstab D., Bowen-Pope D.F., Seifert R.A., Coats S., Hawkins S.M., Clowes A.W. Matrix metalloproteinase-9 overexpression enhances vascular smooth muscle cell migration and alters remodeling in the injured rat carotid artery. Circ. Res. 1999, 85:1179-1185.
175. Masumoto A., Hirooka Y., Hironaga K., Eshima K., Setoguchi S., Egashira K., Takeshita A. Effect of pravastatin on endothelial function in patients with coronary artery disease (cholesterol-independent effect of pravastatin). Am. J. Cardiol. 2001, 88:1291-1294.
176. Matsuoka T., Wada J., Hashimoto I., Zhang Y., Eguchi J., Ogawa N., Shikata K., Kanwar Y.S., Makino H. Gene delivery of Tim44 reduces mitochondrial superoxide production and ameliorates neointimal proliferation of injured carotid artery in diabetic rats. Diabetes 2005, 54:2882-2890.
177. Menini S., Amadio L., Oddi G., Ricci C., Pesce C., Pugliese F., Giorgio M., Migliaccio E., Pelicci P., Iacobini C., Pugliese G. Deletion of p66Shc longevity gene protects against experimental diabetic glomerulopathy by preventing diabetes-induced oxidative stress. Diabetes 2006, 55:1642-1650.
178. Metzler B., Hu Y., Dietrich H., Xu Q. Increased expression and activation of stress-activated protein kinases/c-Jun NH(2)-terminal protein kinases in atherosclerotic lesions coincide with p53. Am. J. Pathol. 2000, 156:1875-1886.
179. Michiels C., Arnould T., Houbion A., Remacle J. Human umbilical vein endothelial cells submitted to hypoxia-reoxygenation in vitro: implication of free radicals, xanthine oxidase, and energy deficiency. J. Cell. Physiol. 1992, 153:53-61.
180. Migliaccio E., Giorgio M., Mele S., Pelicci G., Reboldi P., Pandolfi P.P., Lanfrancone L., Pelicci P.G. The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature 1999, 402:309-313.
181. Milano G., Morel S., Bonny C., Samaja M., von Segesser L.K., Nicod P., Vassalli G. A peptide inhibitor of c-Jun NH2-terminal kinase reduces myocardial ischemia-reperfusion injury and infarct size in vivo. Am. J. Physiol. Heart Circ. Physiol. 2007, 292:H1828-H1835.
182. Miles A.M., Bohle D.S., Glassbrenner P.A., Hansert B., Wink D.A., Grisham M.B. Modulation of superoxide-dependent oxidation and hydroxylation reactions by nitric oxide. J. Biol. Chem. 1996, 271:40-47.
183. Miller Y.I., Chang M.K., Binder C.J., Shaw P.X., Witztum J.L. Oxidized low density lipoprotein and innate immune receptors. Curr. Opin. Lipidol. 2003, 14:437-445.
184. Miller A.A., Drummond G.R., Sobey C.G. Novel isoforms of NADPH-oxidase in cerebral vascular control. Pharmacol. Ther. 2006, 111:928-948.
185. Milstien S., Katusic Z. Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. Biochem. Biophys. Res. Commun. 1999, 263:681-684.
186. Ming X.F., Barandier C., Viswambharan H., Kwak B.R., Mach F., Mazzolai L., Hayoz D., Ruffieux J., Rusconi S., Montani J.P., Yang Z. Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction. Circulation 2004, 110:3708-3714.
187. Moens A.L., Takimoto E., Tocchetti C.G., Chakir K., Bedja D., Cormaci G., Ketner E.A., Majmudar M., Gabrielson K., Halushka M.K., Mitchell J.B., Biswal S., Channon K.M., Wolin M.S., Alp N.J., Paolocci N., Champion H.C., Kass D.A. Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation 2008, 117:2626-2636.
188. Mollnau H., Wendt M., Szocs K., Lassegue B., Schulz E., Oelze M., Li H., Bodenschatz M., August M., Kleschyov A.L., Tsilimingas N., Walter U., Forstermann U., Meinertz T., Griendling K., Munzel T. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ. Res. 2002, 90:E58-E65.
189. Moncada S. The 1991 Ulf von Euler Lecture. The L-arginine: nitric oxide pathway. Acta Physiol. Scand. 1992, 145:201-227.
190. Moncada S., Higgs A. The L-arginine-nitric oxide pathway. N. Engl. J. Med. 1993, 329:2002-2012.
191. Morawietz H., Weber M., Rueckschloss U., Lauer N., Hacker A., Kojda G. Upregulation of vascular NAD(P)H oxidase subunit gp91phox and impairment of the nitric oxide signal transduction pathway in hypertension. Biochem. Biophys. Res. Commun. 2001, 285:1130-1135.
192. Morgenstern D.E., Gifford M.A., Li L.L., Doerschuk C.M., Dinauer M.C. Absence of respiratory burst in X-linked chronic granulomatous disease mice leads to abnormalities in both host defense and inflammatory response to Aspergillus fumigatus. J. Exp. Med. 1997, 185:207-218.
193. Moro M.A., Darley-Usmar V.M., Goodwin D.A., Read N.G., Zamora-Pino R., Feelisch M., Radomski M.W., Moncada S. Paradoxical fate and biological action of peroxynitrite on human platelets. Proc. Natl. Acad. Sci. U S A 1994, 91:6702-6706.
194. Moro M.A., Darley-Usmar V.M., Lizasoain I., Su Y., Knowles R.G., Radomski M.W., Moncada S. The formation of nitric oxide donors from peroxynitrite. Br. J. Pharmacol. 1995, 116:1999-2004.
195. Moulton K.S., Vakili K., Zurakowski D., Soliman M., Butterfield C., Sylvin E., Lo K.M., Gillies S., Javaherian K., Folkman J. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc. Natl. Acad. Sci. U S A 2003, 100:4736-4741.
196. Munzel T., Li H., Mollnau H., Hink U., Matheis E., Hartmann M., Oelze M., Skatchkov M., Warnholtz A., Duncker L., Meinertz T., Forstermann U. Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability. Circ. Res. 2000, 86:E7-E12.
197. Munzel T., Genth-Zotz S., Hink U. Targeting heme-oxidized soluble guanylate cyclase: solution for all cardiorenal problems in heart failure?. Hypertension 2007, 49:974-976.
198. Munzel T., Sinning C., Post F., Warnholtz A., Schulz E. Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann. Med. 2008, 40:180-196.
199. Murray C.J., Lopez A.D. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997, 349:1269-1276.
200. Nakazono K., Watanabe N., Matsuno K., Sasaki J., Sato T., Inoue M. Does superoxide underlie the pathogenesis of hypertension?. Proc. Natl. Acad. Sci. U S A 1991, 88:10045-10048.
201. Napoli C., Martin-Padura I., de Nigris F., Giorgio M., Mansueto G., Somma P., Condorelli M., Sica G., De Rosa G., Pelicci P. Deletion of the p66Shc longevity gene reduces systemic and tissue oxidative stress, vascular cell apoptosis, and early atherogenesis in mice fed a high-fat diet. Proc. Natl. Acad. Sci. U S A 2003, 100:2112-2116.
202. Nathan C. Specificity of a third kind: reactive oxygen and nitrogen intermediates in cell signaling. J. Clin. Invest. 2003, 111:769-778.
203. Nemoto S., Combs C.A., French S., Ahn B.H., Fergusson M.M., Balaban R.S., Finkel T. The mammalian longevity-associated gene product p66shc regulates mitochondrial metabolism. J. Biol. Chem. 2006, 281:10555-10560.
204. Nickenig G., Baumer A.T., Temur Y., Kebben D., Jockenhovel F., Bohm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999, 100:2131-2134.
205. Nishikawa T., Edelstein D., Du X.L., Yamagishi S., Matsumura T., Kaneda Y., Yorek M.A., Beebe D., Oates P.J., Hammes H.P., Giardino I., Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787-790.
206. Nishino T., Okamoto K., Kawaguchi Y., Hori H., Matsumura T., Eger B.T., Pai E.F., Nishino T. Mechanism of the conversion of xanthine dehydrogenase to xanthine oxidase: identification of the two cysteine disulfide bonds and crystal structure of a non-convertible rat liver xanthine dehydrogenase mutant. J. Biol. Chem. 2005, 280:24888-24894.
207. Niskanen L.K., Laaksonen D.E., Nyyssonen K., Alfthan G., Lakka H.M., Lakka T.A., Salonen J.T. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch. Intern. Med. 2004, 164:1546-1551.
208. Ohara Y., Peterson T.E., Harrison D.G. Hypercholesterolemia increases endothelial superoxide anion production. J. Clin. Invest. 1993, 91:2546-2551.
209. Opie L. The Heart: Physiology, from Cell to Circulation 1998, Lippincott Williams & Wilkins.
210. Opitz N., Drummond G.R., Selemidis S., Meurer S., Schmidt H.H. The 'A's and 'O's of NADPH oxidase regulation: a commentary on "Subcellular localization and function of alternatively spliced Noxo1 isoforms". Free Radic. Biol. Med. 2007, 42:175-179.
211. Osterud B., Bjorklid E. Role of monocytes in atherogenesis. Physiol. Rev. 2003, 83:1069-1112.
212. Osto E., Kouroedov A., Mocharla P., Akhmedov A., Besler C., Rohrer L., von Eckardstein A., Iliceto S., Volpe M., Luscher T.F., Cosentino F. Inhibition of protein kinase Cbeta prevents foam cell formation by reducing scavenger receptor A expression in human macrophages. Circulation 2008, 118:2174-2182.
213. Osto E., Matter C.M., Kouroedov A., Malinski T., Bachschmid M., Camici G.G., Kilic U., Stallmach T., Boren J., Iliceto S., Luscher T.F., Cosentino F. c-Jun N-terminal kinase 2 deficiency protects against hypercholesterolemia-induced endothelial dysfunction and oxidative stress. Circulation 2008, 118:2073-2080.
214. Ottaviano F.G., Handy D.E., Loscalzo J. Redox regulation in the extracellular environment. Circ. J 2008, 72:1-16.
215. O'Driscoll J.G., Green D.J., Rankin J.M., Taylor R.R. Nitric oxide-dependent endothelial function is unaffected by allopurinol in hypercholesterolaemic subjects. Clin. Exp. Pharmacol. Physiol. 1999, 26:779-783.
216. Pacini S., Pellegrini M., Migliaccio E., Patrussi L., Ulivieri C., Ventura A., Carraro F., Naldini A., Lanfrancone L., Pelicci P., Baldari C.T. p66SHC promotes apoptosis and antagonizes mitogenic signaling in T cells. Mol. Cell Biol. 2004, 24:1747-1757.
217. Packard R.R., Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin. Chem. 2008, 54:24-38.
218. Pagnin E., Fadini G., de Toni R., Tiengo A., Calo L., Avogaro A. Diabetes induces p66shc gene expression in human peripheral blood mononuclear cells: relationship to oxidative stress. J. Clin. Endocrinol Metab. 2005, 90:1130-1136.
219. Panza, J. (1999). "Endothelium, nitric oxide, and atherosclerosis.".
220. Paravicini T.M., Touyz R.M. Redox signaling in hypertension. Cardiovasc Res. 2006, 71:247-258.
221. Paravicini T.M., Touyz R.M. NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care 2008, 31(Suppl 2):S170-S180.
222. Patetsios P., Song M., Shutze W.P., Pappas C., Rodino W., Ramirez J.A., Panetta T.F. Identification of uric acid and xanthine oxidase in atherosclerotic plaque. Am. J. Cardiol. 2001, 88:188-191. A6.
223. Pieper G.M., Dondlinger L.A. Plasma and vascular tissue arginine are decreased in diabetes: acute arginine supplementation restores endothelium-dependent relaxation by augmenting cGMP production. J. Pharmacol. Exp. Ther. 1997, 283:684-691.
224. Pinton P., Rimessi A., Marchi S., Orsini F., Migliaccio E., Giorgio M., Contursi C., Minucci S., Mantovani F., Wieckowski M.R., Del Sal G., Pelicci P.G., Rizzuto R. Protein kinase C beta and prolyl isomerase 1 regulate mitochondrial effects of the life-span determinant p66Shc. Science 2007, 315:659-663.
225. Pollock J.S., Forstermann U., Mitchell J.A., Warner T.D., Schmidt H.H., Nakane M., Murad F. Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc. Natl. Acad. Sci. U S A 1991, 88:10480-10484.
226. Pou S., Pou W.S., Bredt D.S., Snyder S.H., Rosen G.M. Generation of superoxide by purified brain nitric oxide synthase. J. Biol. Chem. 1992, 267:24173-24176.
227. Pritchard K.A., Groszek L., Smalley D.M., Sessa W.C., Wu M., Villalon P., Wolin M.S., Stemerman M.B. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ. Res. 1995, 77:510-518.
228. Puddu P., Puddu G.M., Galletti L., Cravero E., Muscari A. Mitochondrial dysfunction as an initiating event in atherogenesis: a plausible hypothesis. Cardiology 2005, 103:137-141.
229. Quyyumi A.A., Dakak N., Andrews N.P., Husain S., Arora S., Gilligan D.M., Panza J.A., Cannon R.O. Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. J. Clin. Invest. 1995, 95:1747-1755.
230. Quyyumi A.A., Mulcahy D., Andrews N.P., Husain S., Panza J.A., Cannon R.O. Coronary vascular nitric oxide activity in hypertension and hypercholesterolemia. Comparison of acetylcholine and substance P. Circulation 1997, 95:104-110.
231. Rabelink T.J., Luscher T.F. Endothelial nitric oxide synthase: host defense enzyme of the endothelium?. Arterioscler Thromb Vasc. Biol. 2006, 26:267-271.
232. Rahaman S.O., Lennon D.J., Febbraio M., Podrez E.A., Hazen S.L., Silverstein R.L. A CD36-dependent signaling cascade is necessary for macrophage foam cell formation. Cell Metab. 2006, 4:211-221.
233. Rajagopalan S., Kurz S., Munzel T., Tarpey M., Freeman B.A., Griendling K.K., Harrison D.G. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J. Clin. Invest. 1996, 97:1916-1923.
234. Rajavashisth T.B., Liao J.K., Galis Z.S., Tripathi S., Laufs U., Tripathi J., Chai N.N., Xu X.P., Jovinge S., Shah P.K., Libby P. Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. J. Biol. Chem. 1999, 274:11924-11929.
235. Rask-Madsen C., King G.L. Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance. Arterioscler Thromb Vasc. Biol. 2005, 25:487-496.
236. Ricci R., Sumara G., Sumara I., Rozenberg I., Kurrer M., Akhmedov A., Hersberger M., Eriksson U., Eberli F.R., Becher B., Boren J., Chen M., Cybulsky M.I., Moore K.J., Freeman M.W., Wagner E.F., Matter C.M., Luscher T.F. Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis. Science 2004, 306:1558-1561.
237. Rodriguez C., Slevin M., Rodriguez-Calvo R., Kumar S., Krupinski J., Tejerina T., Martinez-Gonzalez J. Modulation of endothelium and endothelial progenitor cell function by low-density lipoproteins: implication for vascular repair, angiogenesis and vasculogenesis. Pathobiology 2009, 76:11-22.
238. Romero M.J., Platt D.H., Caldwell R.B., Caldwell R.W. Therapeutic use of citrulline in cardiovascular disease. Cardiovasc Drug Rev. 2006, 24:275-290.
239. Romero M.J., Platt D.H., Tawfik H.E., Labazi M., El-Remessy A.B., Bartoli M., Caldwell R.B., Caldwell R.W. Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ. Res. 2008, 102:95-102.
240. Ron D., Kazanietz M.G. New insights into the regulation of protein kinase C and novel phorbol ester receptors. FASEB J 1999, 13:1658-1676.
241. Rossitch E., Alexander E., Black P.M., Cooke J.P. L-arginine normalizes endothelial function in cerebral vessels from hypercholesterolemic rabbits. J. Clin. Invest. 1991, 87:1295-1299.
242. Rota M., LeCapitaine N., Hosoda T., Boni A., De Angelis A., Padin-Iruegas M.E., Esposito G., Vitale S., Urbanek K., Casarsa C., Giorgio M., Luscher T.F., Pelicci P.G., Anversa P., Leri A., Kajstura J. Diabetes promotes cardiac stem cell aging and heart failure, which are prevented by deletion of the p66shc gene. Circ. Res. 2006, 99:42-52.
243. Ryden L., Standl E., Bartnik M., Van den Berghe G., Betteridge J., de Boer M.J., Cosentino F., Jonsson B., Laakso M., Malmberg K., Priori S., Ostergren J., Tuomilehto J., Thrainsdottir I., Vanhorebeek I., Stramba-Badiale M., Lindgren P., Qiao Q., Priori S.G., Blanc J.J., Budaj A., Camm J., Dean V., Deckers J., Dickstein K., Lekakis J., McGregor K., Metra M., Morais J., Osterspey A., Tamargo J., Zamorano J.L., Deckers J.W., Bertrand M., Charbonnel B., Erdmann E., Ferrannini E., Flyvbjerg A., Gohlke H., Juanatey J.R., Graham I., Monteiro P.F., Parhofer K., Pyorala K., Raz I., Schernthaner G., Volpe M., Wood D. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur. Heart J 2007, 28:88-136.
244. Sarkar R., Meinberg E.G., Stanley J.C., Gordon D., Webb R.C. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ. Res. 1996, 78:225-230.
245. Sata M., Walsh K. Oxidized LDL activates fas-mediated endothelial cell apoptosis. J. Clin. Invest. 1998, 102:1682-1689.
246. Schmidt-Lucke C., Rossig L., Fichtlscherer S., Vasa M., Britten M., Kamper U., Dimmeler S., Zeiher A.M. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005, 111:2981-2987.
247. Schober A. Chemokines in vascular dysfunction and remodeling. Arterioscler Thromb Vasc. Biol. 2008, 28:1950-1959.
248. Sheetz M.J., King G.L. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002, 288:2579-2588.
249. Simon A., Plies L., Habermeier A., Martine U., Reining M., Closs E.I. Role of neutral amino acid transport and protein breakdown for substrate supply of nitric oxide synthase in human endothelial cells. Circ. Res. 2003, 93:813-820.
250. Simonet S., Rupin A., Badier-Commander C., Coumailleau S., Behr-Roussel D., Verbeuren T.J. Evidence for superoxide anion generation in aortas of cholesterol-fed rabbits treated with L-arginine. Eur. J. Pharmacol. 2004, 492:211-216.
251. Skalen K., Gustafsson M., Rydberg E.K., Hulten L.M., Wiklund O., Innerarity T.L., Boren J. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002, 417:750-754.
252. Skulachev V.P. Uncoupling: new approaches to an old problem of bioenergetics. Biochim. Biophys. Acta 1998, 1363:100-124.
253. Sorescu D., Weiss D., Lassegue B., Clempus R.E., Szocs K., Sorescu G.P., Valppu L., Quinn M.T., Lambeth J.D., Vega J.D., Taylor W.R., Griendling K.K. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 2002, 105:1429-1435.
254. Spiecker M., Peng H.B., Liao J.K. Inhibition of endothelial vascular cell adhesion molecule-1 expression by nitric oxide involves the induction and nuclear translocation of IkappaBalpha. J. Biol. Chem. 1997, 272:30969-30974.
255. Spiekermann S., Landmesser U., Dikalov S., Bredt M., Gamez G., Tatge H., Reepschlager N., Hornig B., Drexler H., Harrison D.G. Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation 2003, 107:1383-1389.
256. Spolarics Z., Bond J.S. Comparison of biochemical properties of liver arginase from streptozocin-induced diabetic and control mice. Arch. Biochem. Biophys. 1989, 274:426-433.
257. Starling E.H., Visscher M.B. The regulation of the energy output of the heart. J. Physiol. 1927, 62:243-261.
258. Steffel J., Luscher T.F., Tanner F.C. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 2006, 113:722-731.
259. Steffen Y., Jung T., Klotz L.O., Schewe T., Grune T., Sies H. Protein modification elicited by oxidized low-density lipoprotein (LDL) in endothelial cells: protection by (-)-epicatechin. Free Radic. Biol. Med. 2007, 42:955-970.
260. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 1989, 320:915-924.
261. Steinbrecher U.P., Parthasarathy S., Leake D.S., Witztum J.L., Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc. Natl. Acad. Sci. U S A 1984, 81:3883-3887.
262. Stroes E., Kastelein J., Cosentino F., Erkelens W., Wever R., Koomans H., Luscher T., Rabelink T. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J. Clin. Invest. 1997, 99:41-46.
263. Subbaramaiah K., Chung W.J., Michaluart P., Telang N., Tanabe T., Inoue H., Jang M., Pezzuto J.M., Dannenberg A.J. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J. Biol. Chem. 1998, 273:21875-21882.
264. Sydow K., Munzel T. ADMA and oxidative stress. Atheroscler 2003, 4(Suppl):41-51.
265. Szocs K., Lassegue B., Sorescu D., Hilenski L.L., Valppu L., Couse T.L., Wilcox J.N., Quinn M.T., Lambeth J.D., Griendling K.K. Upregulation of Nox-based NAD(P)H oxidases in restenosis after carotid injury. Arterioscler Thromb. Vasc. Biol. 2002, 22:21-27.
266. Takeya R., Sumimoto H. Regulation of novel superoxide-producing NAD(P)H oxidases. Antioxid Redox Signal 2006, 8:1523-1532.
267. Tayeh M.A., Marletta M.A. Macrophage oxidation of L-arginine to nitric oxide, nitrite, and nitrate. Tetrahydrobiopterin is required as a cofactor. J. Biol. Chem. 1989, 264:19654-19658.
268. Tesfamariam B. Free radicals in diabetic endothelial cell dysfunction. Free Radic. Biol. Med. 1994, 16:383-391.
269. Tesfamariam B., Brown M.L., Cohen R.A. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J. Clin. Invest. 1991, 87:1643-1648.
270. Thomas S.R., Witting P.K., Drummond G.R. Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal 2008, 10:1713-1765.
271. Tonetti M.S., D'Aiuto F., Nibali L., Donald A., Storry C., Parkar M., Suvan J., Hingorani A.D., Vallance P., Deanfield J. Treatment of periodontitis and endothelial function. N. Engl. J. Med. 2007, 356:911-920.
272. Touyz R.M., Yao G. Up-regulation of vascular and renal mitogen-activated protein kinases in hypertensive rats is normalized by inhibitors of the Na+/Mg2+ exchanger. Clin. Sci. (Lond) 2003, 105:235-242.
273. Touyz R.M., Yao G., Schiffrin E.L. c-Src induces phosphorylation and translocation of p47phox: role in superoxide generation by angiotensin II in human vascular smooth muscle cells. Arterioscler Thromb. Vasc. Biol. 2003, 23:981-987.
274. Touyz R.M., Yao G., Viel E., Amiri F., Schiffrin E.L. Angiotensin II and endothelin-1 regulate MAP kinases through different redox-dependent mechanisms in human vascular smooth muscle cells. J. Hypertens 2004, 22:1141-1149.
275. Tricot O., Mallat Z., Heymes C., Belmin J., Leseche G., Tedgui A. Relation between endothelial cell apoptosis and blood flow direction in human atherosclerotic plaques. Circulation 2000, 101:2450-2453.
276. Tschudi M.R., Barton M., Bersinger N.A., Moreau P., Cosentino F., Noll G., Malinski T., Luscher T.F. Effect of age on kinetics of nitric oxide release in rat aorta and pulmonary artery. J. Clin. Invest. 1996, 98:899-905.
277. Vanhoutte P.M. Aging and vascular responsiveness. J. Cardiovasc. Pharmacol. 1988, 12(Suppl 8):S11-S19.
278. Vasa M., Fichtlscherer S., Aicher A., Adler K., Urbich C., Martin H., Zeiher A.M., Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ. Res. 2001, 89:E1-E7.
279. Vasquez-Vivar J., Kalyanaraman B., Martasek P., Hogg N., Masters B.S., Karoui H., Tordo P., Pritchard K.A. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc. Natl. Acad. Sci. U S A 1998, 95:9220-9225.
280. Vasquez-Vivar J., Martasek P., Whitsett J., Joseph J., Kalyanaraman B. The ratio between tetrahydrobiopterin and oxidized tetrahydrobiopterin analogues controls superoxide release from endothelial nitric oxide synthase: an EPR spin trapping study. Biochem. J 2002, 362:733-739.
281. Veresh Z., Racz A., Lotz G., Koller A. ADMA impairs nitric oxide-mediated arteriolar function due to increased superoxide production by angiotensin II-NAD(P)H oxidase pathway. Hypertension 2008, 52:960-966.
282. Verhaar M.C., Stroes E., Rabelink T.J. Folates and cardiovascular disease. Arterioscler Thromb. Vasc. Biol. 2002, 22:6-13.
283. Vinik A. The protein kinase C-beta inhibitor, ruboxistaurin, for the treatment of diabetic microvascular complications. Expert Opin. Investig. Drugs 2005, 14:1547-1559.
284. Virdis A., Neves M.F., Amiri F., Touyz R.M., Schiffrin E.L. Role of NAD(P)H oxidase on vascular alterations in angiotensin II-infused mice. J. Hypertens 2004, 22:535-542.
285. Virmani R., Kolodgie F.D., Burke A.P., Finn A.V., Gold H.K., Tulenko T.N., Wrenn S.P., Narula J. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb. Vasc. Biol. 2005, 25:2054-2061.
286. Walker H.A., McGing E., Fisher I., Boger R.H., Bode-Boger S.M., Jackson G., Ritter J.M., Chowienczyk P.J. Endothelium-dependent vasodilation is independent of the plasma L-arginine/ADMA ratio in men with stable angina: lack of effect of oral L-arginine on endothelial function, oxidative stress and exercise performance. J. Am. Coll. Cardiol. 2001, 38:499-505.
287. Warnholtz A., Nickenig G., Schulz E., Macharzina R., Brasen J.H., Skatchkov M., Heitzer T., Stasch J.P., Griendling K.K., Harrison D.G., Bohm M., Meinertz T., Munzel T. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 1999, 99:2027-2033.
288. Wassmann S., Laufs U., Muller K., Konkol C., Ahlbory K., Baumer A.T., Linz W., Bohm M., Nickenig G. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb. Vasc. Biol. 2002, 22:300-305.
289. Wassmann S., Werner N., Czech T., Nickenig G. Improvement of endothelial function by systemic transfusion of vascular progenitor cells. Circ. Res. 2006, 99:e74-e83.
290. Wenzel P., Schuhmacher S., Kienhofer J., Muller J., Hortmann M., Oelze M., Schulz E., Treiber N., Kawamoto T., Scharffetter-Kochanek K., Munzel T., Burkle A., Bachschmid M.M., Daiber A. Manganese superoxide dismutase and aldehyde dehydrogenase deficiency increase mitochondrial oxidative stress and aggravate age-dependent vascular dysfunction. Cardiovasc. Res. 2008, 80:280-289.
291. Werner N., Kosiol S., Schiegl T., Ahlers P., Walenta K., Link A., Bohm M., Nickenig G. Circulating endothelial progenitor cells and cardiovascular outcomes. N. Engl. J. Med. 2005, 353:999-1007.
292. Williams S.B., Goldfine A.B., Timimi F.K., Ting H.H., Roddy M.A., Simonson D.C., Creager M.A. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998, 97:1695-1701.
293. Wolin M.S., Ahmad M., Gupte S.A. Oxidant and redox signaling in vascular oxygen sensing mechanisms: basic concepts, current controversies, and potential importance of cytosolic NADPH. Am. J. Physiol. Lung Cell Mol. Physiol. 2005, 289:L159-L173.
294. Wu K.K., Hatzakis H., Lo S.S., Seong D.C., Sanduja S.K., Tai H.H. Stimulation of de novo synthesis of prostaglandin G/H synthase in human endothelial cells by phorbol ester. J. Biol. Chem. 1988, 263:19043-19047.
295. Xu Q., Liu Y., Gorospe M., Udelsman R., Holbrook N.J. Acute hypertension activates mitogen-activated protein kinases in arterial wall. J. Clin. Invest. 1996, 97:508-514.
296. Xu W., Kaneko F.T., Zheng S., Comhair S.A., Janocha A.J., Goggans T., Thunnissen F.B., Farver C., Hazen S.L., Jennings C., Dweik R.A., Arroliga A.C., Erzurum S.C. Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J 2004, 18:1746-1748.
297. Yan Z.Q., Sirsjo A., Bochaton-Piallat M.L., Gabbiani G., Hansson G.K. Augmented expression of inducible NO synthase in vascular smooth muscle cells during aging is associated with enhanced NF-kappaB activation. Arterioscler Thromb. Vasc. Biol. 1999, 19:2854-2862.
298. Yoshimura K., Aoki H., Ikeda Y., Fujii K., Akiyama N., Furutani A., Hoshii Y., Tanaka N., Ricci R., Ishihara T., Esato K., Hamano K., Matsuzaki M. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat. Med. 2005, 11:1330-1338.
299. Yoshimura K., Aoki H., Ikeda Y., Furutani A., Hamano K., Matsuzaki M. Identification of c-Jun N-terminal kinase as a therapeutic target for abdominal aortic aneurysm. Ann. N Y Acad. Sci. 2006, 1085:403-406.
300. Yusuf S., Reddy S., Ounpuu S., Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001, 104:2746-2753.
301. Zeiher A.M., Goebel H., Schachinger V., Ihling C. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. Circulation 1995, 91:941-947.
302. Zhang C. The role of inflammatory cytokines in endothelial dysfunction. Basic Res. Cardiol. 2008, 103:398-406.
303. Zhang C., Hein T.W., Wang W., Chang C.I., Kuo L. Constitutive expression of arginase in microvascular endothelial cells counteracts nitric oxide-mediated vasodilatory function. FASEB J 2001, 15:1264-1266.
304. Zhang C., Hein T.W., Wang W., Miller M.W., Fossum T.W., McDonald M.M., Humphrey J.D., Kuo L. Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. Hypertension 2004, 44:935-943.
305. Zhang C., Hein T.W., Wang W., Ren Y., Shipley R.D., Kuo L. Activation of JNK and xanthine oxidase by TNF-alpha impairs nitric oxide-mediated dilation of coronary arterioles. J. Mol. Cell Cardiol. 2006, 40:247-257.